The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Open accessAbstract
Purpose: Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this study was to compare two chemotherapy regimens for LGGs in children younger than age 10 years for whom radiotherapy was felt by the practitioner to pose a high risk of neurodevelopmental injury. Patients and Methods: Previously untreated children younger than age 10 years with progressive or residual LGGs were eligible. Children were randomly assigned to receive carboplatin and vincristine (CV) or thioguanine, procarbazine, lomustine, and vincristine (TPCV). Children with neurofibromatosis are reported separately. Results: Of 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV. The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% ± 3.2% and 86% ± 2.2%, respectively. The 5-year EFS rates were 39% ± 4% for CV and 52% ± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007). On multivariate analysis, factors independently predictive of worse EFS and OS were younger age and tumor size greater than 3 cm 2. Tumor location in the thalamus was also associated with poor OS. Conclusion: The difference in EFS between the regimens did not reach significance on the basis of the stratified log-rank test. The 5-year EFS was higher for TPCV on the basis of the cure model analysis. Differences in toxicity may influence physician choice of regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Late neurocognitive sequelae in survivors of brain tumours in childhood
Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01507-4 · Cited by 872
Packer, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., et al. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.5.0747 · Cited by 636
Self-citationPollack, I. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312207 · Cited by 556
Self-citationMerchant, T. E., Conklin, H. M., Wu, S., Lustig, R. H., & Xiong, X. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2738 · Cited by 417
Bowers, D. C., Liu, Y., Leisenring, W., McNeil, E., Stovall, M., Gurney, J. G., Robison, L. L., Packer, R. J., & Oeffinger, K. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2884 · Cited by 383
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
Rubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital.
Gajjar, A., Sanford, R. A., Heideman, R., Jenkins, J. J., Walter, A., Li, Y., Langston, J. W., Muhlbauer, M., Boyett, J. M., & Kun, L. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2792 · Cited by 224
Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., et al. (2007) · Cancer · doi:10.1002/cncr.22961 · Cited by 196
Self-citationHigh Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma
Massimino, M., Spreafico, F., Cefalo, G., Riccardi, R., Tesoro-Tess, J. D., Gandola, L., Riva, D., Ruggiero, A., Valentini, L., Mazza, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.087 · Cited by 176
Group sequential procedures: Calendar versus information time
Lan, K. K. G., & Demets, D. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780081003 · Cited by 168
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma
Yu, J., Deshmukh, H., Gutmann, R. J., Emnett, R. J., Rodríguez, F. J., Watson, M. A., Nagarajan, R., & Gutmann, D. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c0664a · Cited by 111
Mulder, R. L., Kremer, L. C. M., van Santen, H. M., Ket, J. L., van Trotsenburg, A. S. P., Koning, C. C. E., Meeteren, A. Y. N. S., Caron, H. N., Neggers, S. J. C. M. M., & van Dalen, E. C. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.004 · Cited by 90
Endocrine outcome in long‐term survivors of low‐grade hypothalamic/chiasmatic glioma
Collett‐Solberg, P. F., Sernyak, H., Satin-Smith, M. S., Katz, L. L., Sutton, L. N., Molloy, P. T., & Moshang, T. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2211032.x · Cited by 79
Moore, B. D., Ater, J. L., & Copeland, D. R. (1992) · Journal of Child Neurology · doi:10.1177/088307389200700308 · Cited by 71
Self-citationTemozolomide in pediatric low‐grade glioma
Khaw, S. L., Coleman, L. T., Downie, P., Heath, J. A., & Ashley, D. M. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21270 · Cited by 59
Walter, A. W., Gajjar, A. J., Reardon, D. A., Thompson, S. J., Langston, J. W., Jones-Wallace, D., Kun, L. E., & Heideman, R. L. (2000) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200005000-00010 · Cited by 28
Cited by
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Neurofibromatosis type 1: a multidisciplinary approach to care
Hirbe, A. C., & Gutmann, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70063-8 · Cited by 626
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Self-citationAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8726 · Cited by 349
Self-citation
Metadata
- Authors
- Ater, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., Vezina, G., Wisoff, J. H., & Pollack, I. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-20
- Volume
- 30
- Issue
- 21
- Pages
- 2641-2647
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106689678
- Cited by
- 433
- References
- 19
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.